Navigation Links
Dendreon Announces Presentation of Data at the American Association of Cancer Research Annual Meeting
Date:4/6/2011

SEATTLE, April 6, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following data presentations taking place at the American Association of Cancer Research (AACR) 102nd Annual Meeting 2011 in Orlando, Florida:

  • Wednesday, April 6, 2011, 8:00 a.m. - 12:00 p.m. ET.  "B lymphocytes are activated during the course of sipuleucel-T treatment, leading to an antigen-specific humoral response."  Poster presentation.
  • Wednesday, April 6, 2011, 8:00 a.m. - 12:00 p.m. ET.  "Evidence of T lymphocyte activation following sipuleucel-T treatment."  Poster presentation.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics.  The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response.  Dendreon's first autologous cellular immunotherapy product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010.  Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer.  The Company is headquartered in Seattle, Washington and has manufacturing facilities in New Jersey, Georgia and California.  Dendreon is traded on the Nasdaq Global Market under the symbol DNDN.  For more information about the Company and its programs, visit http://www.dendreon.com/.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Dendreon Announces Webcast Presentations at Upcoming Conferences
2. Dendreon Expands Launch of PROVENGE
3. Dendreon Announces Exercise and Closing of Overallotment Option
4. Dendreon Announces Offering of $500 Million Convertible Senior Notes Due 2016
5. Dendreon Announces Webcast Presentation at J.P. Morgan Healthcare Conference
6. Dendreon Announces Presentation of PROVENGE Data at the American Society of Hematology and the Society of Urologic Oncology Annual Meetings
7. Dendreon Announces Webcast Presentation at Credit Suisse 2010 Health Care Conference
8. Dendreon Reports Third Quarter 2010 Financial Results
9. Dendreon Announces Presentation of PROVENGE Data at the 25th International Society for Biological Therapy of Cancer Annual Meeting
10. Dendreon Statement on CMS National Coverage Analysis
11. Dendreon Announces Presentation of PROVENGE Data at the American Urological Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 ReportsnReports.com ... 2016" market research report that provides an overview ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
(Date:4/29/2016)... April 29, 2016 Automation is ... laboratory due to the growing demands for productivity in ... contemporary automated systems are already adept of a wide ... tedious and manual labor. Instrumentation continues to evolve, and ... conceivable just a few years ago. Originally used mostly ...
(Date:4/28/2016)... BURLINGAME, Calif. , April 28, 2016 /PRNewswire/ ... first-ever widely accessible breast and ovarian cancer risk ... cancer panel analyzing 30 genes that highly impact ... and women. Available today, the Color Test analyzes ... pancreatic, prostate, stomach, and uterine cancers. The Color ...
Breaking Medicine Technology:
(Date:5/3/2016)... NY (PRWEB) , ... May 04, 2016 , ... ... a 2016-2017 inductee into its VIP Woman of the Year Circle. She is recognized ... organization exclusively for professional women, boasting more than 850,000 members and over 200 operating ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... 2016 Champion Award to Charles D. Pulido, R.Ph., Co-Founder of NCPDP and member ... Ph.D., Pharmacy Advisor and Health IT Specialist, Office of the National Coordinator for ...
(Date:5/3/2016)... ... 2016 , ... California health startup Pegara announced today the ... assess their risk of developing Alzheimer’s disease. Using a questionnaire based on years ... Score™” that summarizes how their lifestyle choices may affect their chances of developing ...
(Date:5/3/2016)... CA (PRWEB) , ... May 03, 2016 , ... ... is a process that selects DNA or RNA from a random library of ... potentially be used as drugs or diagnostic agents. SELEX selection is commonly performed ...
(Date:5/3/2016)... Fla. (PRWEB) , ... May 03, 2016 , ... Elizabeth ... her pet parrots to join her with one on her shoulder and one on ... through a parking lot because of years of mitral valve prolapse. , The valves ...
Breaking Medicine News(10 mins):